SCHEMBL7273533

SCHEMBL7273533

Nc1ccc(C2=NNC(=O)CC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.68
KCNH2 Q12809 1/20 0.58
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
NPY1R P25929 1/20 0.55
NPY2R P49146 1/20 0.55
PDE3B Q13370 12/20 0.54
PDE3A Q14432 12/20 0.54
PDE4A P27815 4/20 0.54
PDE4B Q07343 4/20 0.54
PDE4C Q08493 4/20 0.54
PDE4D Q08499 4/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
CYP2C19 P33261 1/20 0.54
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7312770 0.98 SMN1; SMN2 (0.66) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL10353452 0.90 SMN1; SMN2 (0.81) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL927560 0.83 SMN1; SMN2 (0.70) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL9687996 0.83 SMN1; SMN2 (0.70) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL13335345 0.83 AXL (0.67) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL20702821 0.82 PDE3B (0.65) SMN1; SMN2PDE3BPDE3APDE4APDE4B
SCHEMBL20702777 0.82 PDE3B (0.52) SMN1; SMN2PDE3BPDE3APDE4APDE4B
SCHEMBL10757285 0.82 SMN1; SMN2 (0.51) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL10757273 0.82 SMN1; SMN2 (0.51) SMN1; SMN2KCNH2LMNAMAPTNPY1R
SCHEMBL7297347 0.82 SMN1; SMN2 (0.58) SMN1; SMN2KCNH2LMNAMAPTNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0175363-B1 4,5-DIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1990-01-17 EP claimed
EP-0175363-A2 4,5-Dihydro-3(2H)-pyridazinones, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1986-03-26 EP claimed
US-12612372-B2 Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-04-28 US disclosed
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 CN disclosed
CN-113980001-B Pyrazolol-pyridazinone coupling compound, pharmaceutical composition thereof and application of pyrazolol-pyridazinone coupling compound in medicines 贵州医科大学 2024-01-30 CN disclosed
US-20230278963-A1 NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-07 US disclosed
EP-4169909-A1 NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF Korea Institute of Science and Technology (KR) 2023-04-26 EP disclosed
CN-115867279-A Novel oxopyridazinyl-phenyl-carbohydrazone acyldinitrile compounds and use thereof 韩国科学技术研究院 2023-03-28 CN disclosed
CN-110117257-B P2Y12 receptor antagonist containing guanidyl as well as preparation method and application thereof 安徽省新星药物开发有限责任公司 2022-12-06 CN disclosed
US-11512056-B2 Guanidyl-containing P2Y12 receptor antagonist and preparation method and application thereof ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD (CN) 2022-11-29 US disclosed
US-4397854-A INCREASE IN MYOCARDIAL CONTRACTILITY WARNER-LAMBERT COMPANY (US) 1983-08-09 US disclosed
EP-0075436-A1 Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted)phenyl-3(2H)-pyridazinones WARNER-LAMBERT COMPANY (US) 1983-03-30 EP disclosed
US-4376771-A ANTI-HYPERTENSIVE AGENTS AND ANTI-THROMBOTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 1983-03-15 US disclosed
EP-0042513-A1 Dihydropyridazinones, processes for their preparation and pharmaceutical compositions containing these compounds BASF Aktiengesellschaft (DE) 1981-12-30 EP disclosed
EP-0042107-A1 Dihydropyridazinones, processes for their preparation and pharmaceutical compositions containing these compounds BASF Aktiengesellschaft (DE) 1981-12-23 EP disclosed
EP-0000113-B1 DIHYDROPYRIDAZONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM AND DIHYDROPYRIDAZONES FOR USE IN MEDICAL TREATMENTS BASF Aktiengesellschaft (DE) 1981-09-16 EP disclosed
EP-0012338-A1 Dihydropyridazinones, process for their preparation and therapeutical agents containing them BASF Aktiengesellschaft (DE) 1980-06-25 EP disclosed
EP-0000113-A1 Dihydropyridazones, their preparation and medicines containing them and dihydropyridazones for use in medical treatments BASF Aktiengesellschaft (DE) 1979-01-10 EP disclosed
US-4052395-A AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES SANKYO COMPANY LIMITED (JA) 1977-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612372-B2 Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof MAPT, MAP2, MAP1B SMN1; SMN2 87/4885KCNH2 662/4885LMNA 2322/4885
US-20230278963-A1 NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF DPP4, QDPR, DPYD SMN1; SMN2 4686/4885KCNH2 123/4885LMNA 3728/4885
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 SMN1; SMN2 4531/4885KCNH2 305/4885LMNA 4524/4885
US-11512056-B2 Guanidyl-containing P2Y12 receptor antagonist and preparation method and application thereof P2RY12, P2RY13, P2RY11 SMN1; SMN2 2584/4885KCNH2 1074/4885LMNA 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.